TABLE 2.
Total Dollars Applied to Pharmacy Claims by Enrollment in Manufacturer Patient Assistance Programs, Copay Cards, and Foundation Grants
| Manufacturer patient assistance programs | |||||||||||||
| Claims, n | Mean ± SD, $ | Median, $ | Range, $ | Total, $ | |||||||||
| Dasatinib | 6 | 11,322 ± 4,448 | 12,414 | 2,244-13,138 | 67,934 | ||||||||
| Abiraterone | 13 | 9,301 ± 212 | 9,360 | 8,595-9,360 | 120,915 | ||||||||
| Filagrastim and filagrastim-sndz | 5 | 3,646 ± 311 | 3,939 | 2,843-3,570 | 15,360 | ||||||||
| Ribociclib | 1 | 11,828 | 11,828 | 11,828 | 11,828 | ||||||||
| Total | 25 | 8,642 ± 3,616 | 9,359 | 2,244-11,828 | 216,037 | ||||||||
| Copay cards | |||||||||||||
| Claims, n | Mean ± SD | Median, $ | Range, $ | Total, $ | Average Out-of-Pocket Cost Before Enrollment | Average Percentage Saved After Enrollment | |||||||
| Peg-filgrastim | 18 | 782 ± 1,000 | 125 | 30-3,120 | 14,076 | 782 | 100 | ||||||
| Dasatinib | 3 | 117 ± 29 | 101 | 100-151 | 351 | 117 | 100 | ||||||
| Filagrastim and filagrastim-sndz | 7 | 926 ± 1,401 | 100 | 50-2,976 | 6,486 | 926 | 100 | ||||||
| Venetoclax | 6 | 76 | 76 | 76 | 456 | 101 | 75 | ||||||
| Everolimus | 4 | 239±279 | 100 | 100-657 | 957 | 239 | 100 | ||||||
| Afatinib | 4 | 5 | 5 | 5 | 20 | 30 | 17 | ||||||
| Lapatinib | 4 | 667±730 | 667 | 35-1,304 | 2,670 | 680 | 99 | ||||||
| Imatinib | 3 | 703 ± 495 | 700 | 210-1,200 | 2,110 | 2,186 | 66 | ||||||
| Ruxolitinib | 2 | 423±527 | 423 | 50-796 | 846 | 448 | 81 | ||||||
| Ibrutinib | 2 | 1,089 ± 229 | 1,089 | 926-1,251 | 2,177 | 1,098 | 99 | ||||||
| Palbociclib | 2 | 3,692 ± 993 | 3,692 | 2,990-4,395 | 7,385 | 3,702 | 99 | ||||||
| Rucaparib | 2 | 40 ± 14 | 40 | 30-50 | 80 | 40 | 100 | ||||||
| Eltrombopag | 2 | 35 | 35 | 35 | 70 | 60 | 58 | ||||||
| Enzalutamide | 1 | 231 | 231 | 231 | 231 | 251 | 92 | ||||||
| Erlotinib | 1 | 3,326 | 3,326 | 3,326 | 3,326 | 3,351 | 99 | ||||||
| Pazopanib | 1 | 75 | 75 | 75 | 75 | 100 | 75 | ||||||
| Ribociclib | 1 | 30 | 30 | 30 | 30 | 30 | 100 | ||||||
| Midostaurin | 1 | 40 | 40 | 40 | 40 | 50 | 80 | ||||||
| Nilotinib | 1 | 30 | 30 | 30 | 30 | 40 | 75 | ||||||
| Total | 65 | 637 ± 1,029 | 100 | 5-4,395 | 41,416 | 709 | 88 | ||||||
| Foundation grants | |||||||||||||
| Palbociclib | 12 | 1,115 ± 1,028 | 552 | 547-3,022 | 13,379 | 1,115 | 100 | ||||||
| Dasatinib | 8 | 352 ± 282 | 399 | 60-613 | 2,816 | 365 | 100 | ||||||
| Ruxolitinib | 6 | 978±987 | 588 | 555-2,995 | 5,870 | 978 | 100 | ||||||
| Enzalutamide | 6 | 706 ± 917 | 500 | 60-2,529 | 4,235 | 706 | 100 | ||||||
| Erlotinib | 5 | 393 | 393 | 393 | 1,965 | 398 | 99 | ||||||
| Cabozantinib | 5 | 1,136 ± 871 | 756 | 720-2,696 | 5,683 | 1,136 | 100 | ||||||
| Pazopanib | 4 | 1,752 ± 1,393 | 1,730 | 547-3,004 | 7,011 | 1,752 | 100 | ||||||
| Vismodegib | 4 | 1,142 ± 1,187 | 548 | 548-2,923 | 4,568 | 1,142 | 100 | ||||||
| Venetoclax | 3 | 742 ± 1,048 | 154 | 120-1,952 | 2,226 | 742 | 100 | ||||||
| Abiraterone | 3 | 456 ± 21 | 468 | 432-468 | 1,369 | 456 | 100 | ||||||
| Sorafenib | 3 | 1,349 ± 1,609 | 420 | 420-3,206 | 4,046 | 1,349 | 100 | ||||||
| Filagrastim and filagrastim-sndz | 2 | 1,996 ± 1,699 | 1,996 | 794-3,197 | 3,991 | 1,996 | 100 | ||||||
| Ibrutinib | 2 | 123 ± 88 | 123 | 60-185 | 245 | 123 | 100 | ||||||
| Total | 63 | 911 ±962 | 549 | 60-3,206 | 57,404 | 913 | 99,9 | ||||||
SD = standard deviation.